20/20 BIOLABS, INC. Operating Cash Flow
20/20 BIOLABS, INC. (AIDX) reported Operating Cash Flow of -$1.89 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-14
- 20/20 BIOLABS, INC. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$605.46K.
- 20/20 BIOLABS, INC. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$1.29M.
- 20/20 BIOLABS, INC. net cash provided by (used in) operating activities for the quarter ending 2025-06-30 was -$534.11K.
- 20/20 BIOLABS, INC. net cash provided by (used in) operating activities for the quarter ending 2025-03-31 was -$488.29K.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|
| 2026-06-30 | -$605.46K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | -$1.89M 10-Q · filed 2026-08-14 | |
| 2026-03-31 | -$1.29M 10-Q · filed 2026-05-20 | ||
| 2025-12-31 | -$1.92M POS AM · filed 2026-04-06 | ||
| 2025-06-30 | -$534.11K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | -$1.02M 10-Q · filed 2026-08-14 | |
| 2025-03-31 | -$488.29K 10-Q · filed 2026-05-20 | ||
| 2024-12-31 | -$2.60M POS AM · filed 2026-04-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEOGENOMICS INC (NEO) | United States | $2.514B | -35.96 |